1134822-07-3 Usage
General Description
Kalydeco hydrate is a medication used to treat cystic fibrosis in patients with specific gene mutations. The active ingredient in Kalydeco hydrate is ivacaftor, which works by targeting the defective protein produced by the gene mutation and helping it function more effectively. This medication is taken orally and is available in the form of tablets or granules that can be dissolved in water. Kalydeco hydrate has been shown to improve lung function and reduce the frequency of respiratory infections in patients with cystic fibrosis. Common side effects may include dizziness, headache, and nausea. It is important for patients to be closely monitored by their healthcare provider while taking Kalydeco hydrate to ensure it is working effectively and to manage any potential side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 1134822-07-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,3,4,8,2 and 2 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1134822-07:
(9*1)+(8*1)+(7*3)+(6*4)+(5*8)+(4*2)+(3*2)+(2*0)+(1*7)=123
123 % 10 = 3
So 1134822-07-3 is a valid CAS Registry Number.
1134822-07-3Relevant articles and documents
SOLID FORMS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE
-
Page/Page column 49, (2009/04/25)
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide are described herein, including crystalline forms thereof.
